Type 2 diabetes: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• GLP-1 63
• SGLT2 40
• PPAR 0
• AMPK 2
• DPP-4 7
• PI3K 0
• AKT 0
• GIP 4
• NRF2 0
• mTOR 0
• NLRP3 3
• SIRT1 1
• STAT3 0
• TP53 1
• TNF 0
• MAPK 0
• PCSK9 1
• VEGF 2
• JNK 0
• TLR4 0
• FTO 0
• IL-6 2
• ERK 0
• HIF-1 0
• JAK 0
• HMGB1 0
• APOE 0
• BDNF 0
• IL-1 1
• STING 0
• CTNNB1 0
• GPX4 0
• PTEN 0
• IL-17 1
• STK11 0
• MMP-9 1
• BCL-2 0
• COX-2 0
• MEK 0
• PINK1 0
• CD40 0
• EGFR 0
• PD-1 0
• RANKL 0
• YAP 0
• ATM 0
• FGFR 0
• MET 1
• PD-L1 0
• SNCA 0
• CCR5 0
• CDKN2A 0
• CXCR4 0
• IGF1R 0
• MAPT 0
• METTL3 0
• PNPLA3 0
• ABL1 0
• BACE1 0
• CD38 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Small Bowel Diversion

  NCT06374368· University of Ostrava· Updated 6 Nov 2026

  “Halted for safety concerns after jejuno-colic diversion: frequent and serious late complications, incl. hepatic fibrosis, lean body mass loss and surgical reversal of the anastomosis.”Registry text, quoted unchanged. Source

• Suspended

  Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

  NCT01105858· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Updated 29 Oct 2026

  “Recruitment temporarily paused.”Registry text, quoted unchanged. Source

• Terminated

  Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithm

  NCT07066891· Sun Yat-sen University· Updated 20 Oct 2026

  “Recruitment was stopped early because hospital length-of-stay constraints limited protocol delivery. The PI's decision also took account of the available non-inferiority results.”Registry text, quoted unchanged. Source

• Withdrawn

  Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency

  NCT07786571· Sun Yat-sen University· Updated 16 Oct 2026

  “The study was withdrawn because the protocol was revised and would be replaced by an updated study design, prior to participant enrollment.”Registry text, quoted unchanged. Source

• Withdrawn

  GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Updated 16 Oct 2026

  “poor accrual and funding issues”Registry text, quoted unchanged. Source

• Suspended

  PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)

  NCT07636161· University of Miami· Updated 28 Sept 2026

  “The sponsor has communicated that they may no longer fund this research study. Pending final confirmation if the study will be closed.”Registry text, quoted unchanged. Source

• Withdrawn

  Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

  NCT03508739· University of Pennsylvania· Updated 21 Sept 2026

  “We do not have active funding.”Registry text, quoted unchanged. Source

• Terminated

  A Nutritional Intervention in Police Officers

  NCT02651480· Physicians Committee for Responsible Medicine· Updated 17 Sept 2026

  “Sponsor put plans on hold”Registry text, quoted unchanged. Source

• Terminated

  A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

  NCT07030868· Eli Lilly and Company· Updated 31 Aug 2026

  “Study terminated for strategic business reasons”Registry text, quoted unchanged. Source

• Terminated

  Novel Digital Patient-Reported Outcomes Tool for Diabetes Management

  NCT05884775· NYU Langone Health· Updated 27 Aug 2026

  “Funding was terminated for the study.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Enhancing Telemedicine for T2D

  NCT06740435· University of Pittsburgh· Source

• A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes

  NCT07922330· AstraZeneca· Source

• AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  NCT07533175· Novo Nordisk A/S· Source

• A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  NCT07668336· Eli Lilly and Company· Source

• Evaluating the Effectiveness of a Multi-level Health-Related Social Needs Initiative

  NCT06831162· Vanderbilt University Medical Center· Source

• UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

  NCT07163624· The United Bio-Technology (Hengqin) Co., Ltd.· Source

• A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

  NCT07670416· Hoffmann-La Roche· Source

• Linking Education, Produce Provision, and Community Referrals to Improve Diabetes Care (LINK)

  NCT05472441· Ohio State University· Source

• A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  NCT07595549· Pfizer· Source

• Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

  NCT07866066· Amgen· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 25
• Organoids 3
• Mendelian Randomization Analysis 228
• CRISPR-Cas Systems 5
• Gene Expression Profiling 112
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 8
• Exome Sequencing 12
• Proteomics 148
• Metabolomics 202
• Mass Spectrometry 42
• Flow Cytometry 19
• Immunohistochemistry 50
• Xenograft Model Antitumor Assays 34
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 185
• Machine Learning 193
• Deep Learning 32
• Cohort Studies 1106
• Genome-Wide Association Study 313

• Tissue-resolved transcriptomic and proteomic profiling reveals organ-specific molecular signatures associated with inter-animal variation in glycemic response to metformin in obese diabetic Mongolian gerbils.

  Front Endocrinol (Lausanne), Oct 2026

• Expression Analysis of microRNAs in Peripheral Blood Mononuclear Cells in Type 2 Diabetes.

  Biomolecules, Oct 2026

• Identification of CLOCK and MARK2 as Candidate Blood-Based Biomarkers in Type 2 Diabetes: An Integrated Bulk and Single-Cell Transcriptomic Study.

  Genes (Basel), Oct 2026

• Multi-omics profiling reveals coordinated metabolic and immuno-inflammatory remodeling in a high-fat diet and single-dose streptozotocin-induced mouse model of diabetic cardiomyopathy.

  BMC Cardiovasc Disord, Sept 2026

• Integrative bioinformatics and machine learning reveal hub genes and immune signatures bridging type 2 diabetes mellitus, fracture susceptibility, and osteoblast differentiation dysfunction.

  Mamm Genome, Sept 2026

• Single-cell virtual knockout network perturbation prioritizes candidate regulators of beta-cell functional failure in type 2 diabetes.

  Front Endocrinol (Lausanne), Sept 2026

• Systemic immune-inflammation index is associated with diabetic peripheral neuropathy: evidence from NHANES, an external clinical cohort, and exploratory human nerve gene-expression analysis.

  Front Endocrinol (Lausanne), Sept 2026

• Single-cell profiling of pancreatic islets maps subtype-associated molecular alterations in type 2 diabetes.

  Diabetologia, Sept 2026

• COBRA: cell-type-specific orthogonal batch effect removal algorithm in single cell RNA-sequencing data.

  Bioinformatics, Aug 2026

• Histopathological and Transcriptomic Alterations in Metabolic Organs: A Case Study from a Spontaneously Diabetic Rhesus Macaque.

  Int J Mol Sci, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.